This technology is a set of antibodies that is used with immunohistochemistry techniques to differentiate between tryptophan hydroxylase 1 and 2, enabling scientists to study how the two enzymes are differentially regulated.
Technology Summary
The tryptophan hydroxylase 1 and 2 (TPH1 and TPH2) genes encode enzymes in serotonin biosynthesis. Variants in both genes have been implicated in several neuropsychiatric disorders and personality traits. Prior to the discovery of TPH2 in 2003, it was thought that serotonin levels in the central nervous system were regulated by serotonin synthesis in the peripheral tissues, with TPH1 as the gene driving that mechanism. The ability to differentiate between the two enzymes would allow scientists to study their different regulation mechanisms.
WSU researchers have developed a group of monospecific polyclonal and monoclonal antibodies that allows for differentiation of TPH1 and TPH2 in immunoblotting, immunoprecipitation, and immunocytochemical staining.
Key Advantages
- Allows for studies of differential regulation of TPH1 and TPH2 expression in the brain and periphery
Market Opportunities
Available under license
- TPH1 Polyclonal Antibody
- TPH2 Polyclonal Antibody
Stage of Development
Pre-Clinical
References & Publications
Kuhn et al. J Neurosci (1997)
DOI: 10.1523/JNEUROSCI.17-15-05820.1997
